Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCM - PACE-CME

Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Long-term efficacy and safety of radiofrequency renal denervation
Long-term efficacy and safety of radiofrequency renal denervation
ACC.22
Long-term efficacy and safety of radiofrequency renal denervation
- Felix Mahfoud, MD
A positive view on a negative trial with DOAC after TAVR
A positive view on a negative trial with DOAC after TAVR
ACC.22
A positive view on a negative trial with DOAC after TAVR
- Megan Coylewright, MD
Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM
Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM
ACC.22
Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM
- Florian Rader, MD
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
ACC.22
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
- Brian Bergmark, MD